Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Atlantic American Corporation (AAME): Insights into a Niche Insurance Provider

Atlantic American Corporation (AAME): Insights into a Niche Insurance Provider

Key Takeaways

  • AAME is Atlantic American Corporation, a Nasdaq-listed insurance holding company headquartered in Atlanta, Georgia.
  • The company operates through two segments: American Southern (property and casualty insurance) and Bankers Fidelity (life and health insurance).
  • Medicare Supplement insurance is its largest product line, representing the majority of Bankers Fidelity's net earned premiums.
  • The company distributes products primarily through independent agents, serving niche specialty markets across much of the United States.
  • Atlantic American is a "controlled company," with a significant portion of its common stock held by related family interests.

Getting to Know AAME

Atlantic American Corporation is a publicly traded insurance holding company whose common stock trades on the Nasdaq Global Market under the ticker AAME. Rather than selling insurance directly under a single national brand, the company operates through separately managed subsidiaries that focus on specialty niches within two broad insurance categories: property and casualty coverage, and life and health coverage. Investors follow AAME to gain exposure to a smaller, regionally focused insurer whose financial profile is tied to underwriting results, investment income, and the demographics of the U.S. senior population. When reviewing similar names, I sometimes cross-check with Tickeron’s AI tools to see how the profile stacks up.

Company Background and Structure

Atlantic American Corporation was incorporated in the state of Georgia in 1968, with corporate roots reaching back to 1937. It is headquartered at 4370 Peachtree Road N.E. in Atlanta, Georgia. The company is an insurance holding company, meaning the parent entity itself conducts little direct business; instead, it earns revenue through its operating insurance subsidiaries, which generate premiums, investment income, and management and tax-sharing fees that flow up to the parent.

The business model is built around two principal operating groups. American Southern comprises American Southern Insurance Company and American Safety Insurance Company and focuses on property and casualty insurance. Bankers Fidelity comprises Bankers Fidelity Life Insurance Company, Bankers Fidelity Assurance Company, and Atlantic Capital Life Assurance Company and focuses on life and health insurance. Each group is managed separately and evaluated on its own performance, a structure the company says allows it to respond quickly to market opportunities.

Revenue Drivers and Segment Details

Atlantic American's primary revenue sources are insurance premiums and net investment income from its portfolio of fixed-income securities, equities, and other investments. Its business segments operate in distinct specialty markets.

American Southern (property and casualty). This segment provides commercial automobile liability and physical damage insurance, general liability coverage, surety bonds, and inland marine coverage. A defining feature is its focus on "block accounts" — tailored, multi-year commercial auto programs written for state governments, local municipalities, and large motor pools and fleets that can be individually rated and underwritten. American Southern is licensed to do business in 32 states and the District of Columbia, and it markets through a select group of independent agents as well as direct competitive bidding for governmental programs.

Bankers Fidelity (life and health). This segment offers individual and group whole life insurance, Medicare Supplement insurance, and a range of accident and health products, including hospital indemnity, short-term care, cancer, and critical illness coverages. Health insurance — primarily Medicare Supplement policies — accounts for roughly 84% of Bankers Fidelity's net earned premiums, making the segment highly sensitive to trends in the senior population and Medicare-related regulation. Products are distributed through independent agents and brokers across approximately 46 states. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Position

Atlantic American competes in highly competitive insurance markets against larger, more diversified national carriers. Its positioning relies on specialization rather than scale: it targets well-defined geographic, demographic, and product niches where it can apply focused underwriting expertise. In property and casualty, this means customized programs for government fleets and municipalities. In life and health, it means serving the senior market through independent agents with supplemental and Medicare-related products.

A key indicator of the company's competitive standing is its financial-strength ratings. Its principal insurance subsidiaries have historically held an "A-" (Excellent) financial strength rating from A.M. Best, which supports their ability to write business and attract agents and policyholders.

Why Follow This Name

Investors follow AAME for several reasons. The company offers exposure to the U.S. insurance industry through a small-cap, value-oriented holding company whose earnings are driven by a combination of underwriting results and investment income. Its heavy weighting toward Medicare Supplement and supplemental health products links its long-term growth to the aging U.S. population, a secular demographic trend. The controlled-company structure and concentrated ownership also mean management has significant influence over strategy and capital allocation. For investors interested in a niche, regionally focused insurer with a specialized book of business, the company's business model provides a distinct profile relative to large national insurers.

Risks Worth Noting

Several factors merit attention before investing. Insurance underwriting is inherently uncertain, with results exposed to claim frequency and severity, inflation, and catastrophic events. As a specialty commercial auto writer, American Southern is exposed to loss-cost inflation in liability lines. Bankers Fidelity's reliance on Medicare Supplement products ties results to healthcare costs and to federal and state regulation of the senior market.

The company also faces specific operational and financial-reporting considerations. In its recent SEC filings, Atlantic American has disclosed delays in filing certain periodic reports, Nasdaq notices of noncompliance with continued-listing rules, and identified material weaknesses in internal control over financial reporting. Its reinsurance arrangements are heavily concentrated with a single reinsurer (General Re Life Corporation), and its insurance subsidiaries are subject to state regulatory oversight and capital requirements. The company's controlled status, small market capitalization, and relatively thin trading liquidity are additional factors that can affect volatility and investor experience.

Refining My Research Process

When analyzing names like this one, I find it helpful to run quick screens across the insurance sector using Tickeron’s AI Screener. It lets me filter by fundamentals, technical signals, and industry trends so I can compare AAME more efficiently against peers. The platform combines multiple criteria in one place, which saves time when I’m building or reviewing a watchlist.

Conclusion

Atlantic American Corporation is a specialized insurance holding company operating in two distinct niches: property and casualty coverage for government fleets and municipalities through American Southern, and life and supplemental health insurance for the senior market through Bankers Fidelity. Its market position rests on focused underwriting and independent-agent distribution rather than national scale, and its financial profile is closely tied to underwriting discipline, investment returns, and Medicare-related demographics. While it offers a distinctive small-cap insurance exposure, investors should weigh its concentration in the senior health market, competitive pressures, and disclosed operational and financial-reporting considerations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AAME

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


AAME's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for AAME turned positive on November 10, 2026. Looking at past instances where AAME's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on AAME as a result. In 79 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

Following a +10.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where AAME advanced for three days, in 160 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

Bearish Trend Analysis

The 10-day RSI Indicator for AAME moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 12 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 56 cases where AAME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

AAME moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AAME crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AAME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

AAME broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AAME's P/B Ratio (0.207) is slightly lower than the industry average of (1.337). P/E Ratio (4.826) is within average values for comparable stocks, (19.773). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (0.463). Dividend Yield (0.072) settles around the average of (0.047) among similar stocks. AAME's P/S Ratio (0.134) is slightly lower than the industry average of (1.303).

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. AAME’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AAME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.

Notable companies

The most notable companies in this group are MetLife (NYSE:MET), Prudential Financial (NYSE:PRU), Lincoln National Corp (NYSE:LNC), Genworth Financial (NYSE:GNW).

Industry description

Life insurance companies mainly sell policies that pay a death benefit as a lump sum upon the death of the insured to their beneficiaries. Life insurance policies may be sold as term life, (which guarantees payment of a stated death benefit and expires at the end of a specified term) or permanent /typically whole life (which is more expensive but lasts a lifetime and carries a cash accumulation component). Life insurance firms may also sell long-term disability policies that help to replace the insured individual’s income if they become sick or disabled. Health insurance, on the other hand, helps pay for medical expenses. Anthem, Inc., MetLife, Inc. and Aflac Incorporated are some of the largest U.S. companies in this industry.

Market Cap

The average market capitalization across the Life/Health Insurance Industry is 18.5B. The market cap for tickers in the group ranges from 228.36K to 140.68B. CILJF holds the highest valuation in this group at 140.68B. The lowest valued company is GWGHQ at 228.36K.

High and low price notable news

The average weekly price growth across all stocks in the Life/Health Insurance Industry was -7%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -9%. SNFCA experienced the highest price growth at 0%, while ABX experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the Life/Health Insurance Industry was 56%. For the same stocks of the Industry, the average monthly volume growth was 24% and the average quarterly volume growth was 50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 39
P/E Growth Rating: 65
Price Growth Rating: 56
SMR Rating: 91
Profit Risk Rating: 61
Seasonality Score: 9 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of life, health, property and casualty insurance services

Industry LifeHealthInsurance

Industry
Multi Line Insurance
Address
4370 Peachtree Road, North East
Phone
+1 404 266-5500
Employees
156
Web
https://www.atlam.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.